DOCSLIB.ORG

Advances in Cardiovascular Risk Reduction IMPROVING TREATMENT for PATIENTS with DIABETES

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in Cardiovascular Risk Reduction IMPROVING TREATMENT for PATIENTS with DIABETES NYU School of Medicine Continuing Medical Education THE IRWIN D. MANDEL Advances in Cardiovascular Risk Reduction IMPROVING TREATMENT FOR PATIENTS WITH DIABETES Thursday, May 9, 2019 New York, NY nyulmc.org/cvriskcme Jointly provided by NYU School of Medicine and the New York State Chapter American College of Physicians (NYACP) SPEAKERS COURSE DIRECTOR Edward A. Fisher, MD, PhD, MPH James A. Underberg, MD Leon H. Charney Professor Clinical Assistant Professor Arthur Z. Schwartzbard, MD of Cardiovascular Medicine of Medicine Associate Professor of Medicine Professor of Cell Biology, Medicine, Director, Clinical Lipid Research Microbiology, and Pediatrics Howard Weintraub, MD Director, Preventive Cardiology Director, Marc and Ruti Bell Clinical Professor of Medicine Fellowship Program Vascular Biology Program Clinical Director, Center for the Center for the Prevention of Co-Director, Center for the Prevention Prevention of Cardiovascular Disease Cardiovascular Disease of Cardiovascular Disease Associate Director, Preventive NYU School of Medicine Cardiology Fellowship Program Lauren H. Golden, MD Clinical Associate COURSE PLANNERS Professor of Medicine GUEST SPEAKERS Director, Center for Diabetes Jeffrey S. Berger, MD and Metabolic Health Paul Ridker, MD Edward A. Fisher, MD, Eugene Braunwald PhD, MPH Ira J. Goldberg, MD Professor of Medicine Harvard Medical School Clarissa and Edgar Bronfman, Jr. Mattia Gilmartin, RN, Senior Physician Professor of Endocrinology Brigham and Women’s Hospital PhD, FAAN Director, Division of Endocrinology, Boston, MA Ira J. Goldberg, MD Diabetes and Metabolism Ana M. Mola, RN, PhD, Dennis A. Goodman, MD Clay F. Semenkovich, MD Irene E. and Michael M. Karl Professor ANP-BC, MAACVPR Clinical Professor of Medicine Chief, Division of Endocrinology, Director, Integrative Medicine Lawrence Phillips, MD Metabolism and Lipid Research NY Chapter American Professor of Medicine and of College of Physicians Sean P. Heffron, MD, MSc Cell Biology and Physiology Assistant Professor of Medicine James A. Underberg, MD Washington University in St. Louis School of Medicine Ana M. Mola, RN, PhD, St. Louis, MO NYU LANGONE HEALTH ANP-BC, MAACVPR Clinical Assistant Professor Kenneth Walsh, PhD SPEAKERS of Rehabilitation Medicine Lockhart B. McGuire Professor Jeffrey S. Berger, MD Director, Care Transitions and of Internal Medicine Population Health Management University of Virginia Associate Professor of Charlottesville, VA Medicine and Surgery Director, Cardiovascular Jonathan Newman, MD, MPH Thrombosis Program Eugene Braunwald, MD Co-Director, Center for the Prevention Assistant Professor of Cardiology of Cardiovascular Disease The Irwin D. Mandel Advances in Cardiovascular Risk Reduction COURSE DESCRIPTION • Describe the increased cardiovascular risk in patients with rheumatological diseases, This one-day course will cover state-of-the-art pathogenesis for these findings, and ways to management of patients with cardiovascular risk improve patient outcomes factors, with a focus on prevention. The morning session will highlight the latest scientific and clinical • Summarize the evidence for HDL in atherosclerotic advances in the management of diabetes with regression and describe how HLD alters the topics to include insulin resistance, new approaches inflammation of atherosclerotic plaques to control type 1 and type 2 and side effects of new diabetes drugs. The course will review the TARGET AUDIENCE challenges of treating statin intolerant patients, Cardiologists, endocrinologists, lipidologists, internists, best practices in primary prevention and review the general practice, family practitioners, advanced inflammation hypothesis, and anti-inflammatory practice providers, nurses, and physician trainees therapies for atherosclerosis. A presentation on with an interest in the prevention of heart disease clonal hematopoiesis will include new research on this recently identified age-related disorder. A presentation on rheumatological diseases will Co-Organized by the Division highlight cardiovascular risk prevention strategies of Cardiology and the Division of to manage patients with these inflammatory Endocrinology, Diabetes and Metabolism medical conditions. The course will provide an in- depth look at the latest scientific studies examining LOCATION the atheroprotective properties of HDL on atherosclerotic risk. This year, the featured research- NYU Langone Health oriented presentation will focus on diabetes with a Alumni Hall presentation on the role of vascular lipid metabolism 550 First Avenue in the vascular complications in the diabetic patient. New York, NY 10016 EDUCATIONAL OBJECTIVES COURSE FEES After participating in this activity, clinicians should be Full: $175 able to: Reduced*: $95 • Describe the role of vascular lipid metabolism in the Residents and Fellows: $60 vascular complications in the diabetic patient * Reduced fee applies to all nursing and allied health care • Describe the burden of insulin resistance, scientific professionals, as well as NYU Langone Health Faculty and advances in understanding insulin pathways, and Staff clinical approaches to prevent the onset of T2DM in Please note: This course is eligible for NYU School of patients with insulin resistance Medicine Alumni discount. • Summarize the benefits and possible disadvantages to new pharmacological agents for REGISTRATION diabetes and how to personalize treatments and nyulmc.org/cvriskcme maximize benefits for patients with cardiovascular After 12 pm on May 7, 2019, only onsite registration is co-morbidities available, provided the course has not reached capacity. • Summarize the side effects of GLP1 receptor Onsite registrants will incur an additional $20 charge. Registration is non-transferable. agonists and SLGT2 inhibitors that may impact non adherence and result in adverse clinical outcomes • Discuss the impact of statin intolerance on ELECTRONIC SYLLABUS cardiovascular risk reduction and outline strategies Course syllabus will only be distributed electronically. to manage statin intolerant patients A link will be sent the week of the course where you can view, download or print course information and • Summarize the data relevant to the impact of presentations in advance. This link will also allow you to treatment of hypertension, lipid lowering, as well as view the course syllabus on your smartphone, tablet, dietary change or laptop during the course. Course presentations • Describe how the landmark CANTOS trial provided remain available for one year after the course. the first clinical proof confirming the inflammatory hypothesis of atherothrombosis • Describe how clonal hematopoiesis correlates with an increased risk of atherosclerotic cardiovascular disease REFUND POLICY CREDIT DESIGNATION STATEMENT Submit your request for a refund of course fees more The NYU School of Medicine designates this live than $75 no later than 7 days before the course start activity for a maximum of 7.50 AMA PRA Category date. No refunds will be issued for cancellations or 1 Credits™. Physicians should claim only the credit no-shows after that time. To request a refund, email commensurate with the extent of their participation in [email protected]. A $75 administrative fee will the activity. be deducted. CONTINUING NURSING COURSE CANCELLATION POLICY EDUCATION CONTACT HOURS If a course is cancelled due to inclement weather, This program will award 7.50 continuing nursing insufficient enrollment, or any other reason, NYU education contact hours. Participants must complete SOM will refund registration fees in full. NYU SOM a course evaluation to claim contact hours for this will provide at least two weeks’ advance notice if learning activity. cancelling due to insufficient enrollment and as soon The NYU Meyers College of Nursing Center for as possible in all other circumstances. NYU SOM is Continuing Education in Nursing is accredited as not responsible for any airfare, hotel, or other a provider of continuing nursing education by the non-cancellable costs incurred by the registrant. American Nurses’ Credentialing Center’s Commission on Accreditation. CONTACT INFORMATION NYU School of Medicine PROVIDED BY Phone: 212-263-5295 Jointly provided by NYU School of Medicine and Fax: 212-263-5293 the New York State Chapter American College of Email: [email protected] Physicians (NYACP) CME ACCREDITATION STATEMENT This activity has been planned and implemented in NYU Langone’s Center for the Prevention accordance with the accreditation requirements and of Cardiovascular Disease is a component of policies of the Accreditation Council for Continuing the Leon H. Charney Division of Cardiology. Medical Education through the joint providership To learn more about our Center and programs visit of the NYU School of Medicine and New York State nyulangone.org/cvdprevention Chapter American College of Physicians. The NYU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. AGENDA | Thursday, May 9, 2019 7:45 am Registration and 11:15 Morning Panel Continental Breakfast Course faculty and panel members: Dennis A. Goodman, MD 8:20 Course Director Welcome Sean P. Heffron, MD, MSc Arthur Z. Schwartzbard, MD Ana M. Mola, RN, PhD, ANP-BC, MAACVPR 8:30 Vascular Lipid Metabolism and Chronic Disease 12:00 pm Lunch and Case Conference Clay F. Semenkovich, MD Ira J. Goldberg, MD 9:00 Insulin Resistance 1:00 Primary Prevention Ira J. Goldberg, MD Howard Weintraub, MD 9:30 New Approaches to Control 1:30 Inflammation Therapies
Load more

Recommended publications
  • A Conversation with Eugene Braunwald
    A conversation with Eugene Braunwald Ushma S. Neill J Clin Invest. 2013;123(1):1-2. https://doi.org/10.1172/JCI67778. Conversations with Giants in Medicine Eugene Braunwald (Figure 1) is often called the father of modern cardiology, as he was the first to define the pathophysiology of hypertrophic cardiomyopathy and to demonstrate the salvage of ischemic myocardium following coronary occlusion. The full interview, with many more stories about performing in the opera and his seminal research discoveries, can be seen on the JCI website, http://www.jci.org/kiosk/cgm. JCI: Can you tell us about your path to medical school? Braunwald: I was born in Vienna, Austria, and had an idyllic childhood there with an excellent school, and tutors in English and piano. On March 12, 1938, everything changed because Austria was annexed by Germany. The Nazis came in, and the fury against the Jews played out in a matter of days. It was a very troubling period. We escaped from Austria at the end of July 1938 with a couple of close calls. It was like The Sound of Music — except that there was no music. We ended up in London two days later, literally with just the shirts on our back. When war was declared in September 1939, my brother and I were evacuated to a small village in Northern England. After living with a wonderful family for a couple of months, I got a postcard that our family was going to America. We took the […] Find the latest version: https://jci.me/67778/pdf Conversations with giants in medicine A conversation with Eugene Braunwald Eugene Braunwald (Figure 1) is often carried out in probably 4,000 hospitals in give them relief from severe angina.
    [Show full text]
  • Atherosclerosis: the 21St Century Epidemic
    THE PONTIFICAL ACADEMY OF SCIENCES Working Group on Atherosclerosis: the 21st Century Epidemic 31 May – 1 June 2010 • Casina Pio IV Introduction p . 3 Programme p. 5 Abstracts p. 7 Biographies of Participants p. 12 List of Participants p. 18 Memorandum p. 19 14 EMIA A D C S A C I E A N I T C I I A F I R T V N M O P VAtIcAn cIty 2010 n carrying out its distinctive service, the Pontifical Academy of Sciences always relies on the data coming from science and the Magisterium of Ithe church. In particular, concerning the present study group [on The Signs of Death ], christian Revelation also invites the man of our times, who in many ways seeks the real profound meaning of his existence, to face the theme of death casting his eye beyond human reality in its purest form and opening his mind to the mystery of God. Indeed, it is in the light of God that the human creature better understands himself and his final destiny, the value and meaning of his life, a precious and irreplaceable gift of the almighty Creator. Benedict XVI, Letter dated 8 September 2006 to his venerated Brother H.E. Msgr. Marcelo Sánchez Sorondo, chancellor of the Pontifical Academy of Sciences, con - cerning the working group on The Signs of Death , 11-12 September 2006. 2 INTRODUCTION Atherosclerosis: H.E. Msgr. Marcelo Sánchez Sorondo, Chancellor the 21st Century Epidemic The Pontifical Academy of Sciences he Pontifical Academy of Sciences, whose purpose cerebrovascular disease in developing areas is lower tis to promote the progress of the sciences for the com - compared to the developed world.
    [Show full text]
  • Dr. Eugene Braunwald, World-Renowned Cardiologist, To
    Robert Benchley April 3, 2018 Dr. Eugene Braunwald, World- Renowned Cardiologist, to Speak at Miller School on April 18 Eugene Braunwald, M.D., a world-renowned cardiologist who is the recipient of 22 honorary doctorates and whose h-index of 208 has caused him to be named the most frequently cited author in cardiology by the journal Science Watch, will speak at the University of Miami Miller School of Medicine on Wednesday, April 18. Eugene Braunwald, M.D. Braunwald, who is the Distinguished Hersey Professor of Medicine at Harvard Medical School, and the founding chair of the TIMI Study Group at Boston’s Brigham and Women’s Hospital, will present “The PCSK9 and Cholesterol Story” from 5 to 6 https://physician-news.umiamihealth.org/dr-eugene-braunwald-world-renowned-cardiologist-to-speak-at-miller-school-on-april-18/ 1 / 3 Robert Benchley April 3, 2018 p.m. at the Michael S. Gordon Center for Research in Medical Education, located on the ground floor of the Don Soffer Clinical Research Center. His presentation is sponsored by the Cardiovascular Division of the Miller School’s Department of Medicine. The lecture is open to the entire UM community and to the public. Braunwald trained at New York University School of Medicine and served his medical residency at Johns Hopkins Hospital. He served as chief of cardiology and as clinical director of the National Heart, Lung and Blood Institute, and founding chair of the Department of Medicine at the University of California, San Diego. From 1972 to 1996 he was chairman of the Department of Medicine at Brigham and Women’s Hospital.
    [Show full text]
  • Coronary Thrombolysis and the New Biology
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector 850 JACC Vol. 14, No. 4 October 1989:850-60 PLENARY LECTURE Coronary Thrombolysis and the New Biology BURTON E. SOBEL, MD, FACC St. Louis, Missouri Remarkable progress in the treatment of heart disease is patients with acute evolving infarction, and DeWood and chronicled by the remarks of the distinguished plenary coworkers convincingly documented a high prevalence of session speakers who have addressed the College during the coronary thrombosis in patients with transmural infarction. past 10 years (Table 1). Recently, fibrinolysis has proved to In concert, these observations lent impetus to the burgeon- be a particularly powerful means of treating patients with ing enthusiasm for coronary thrombolysis-an enthusiasm acute myocardial infarction. Accordingly, in this year’s fed also by rapid progress in molecular biology (3). address, it is a privilege to discuss some of the novel and Until recently, the revolution in molecular biology that significant contributions of molecular biology to the progress has had such a profound impact on medicine in general has in coronary thrombolysis. been felt only peripherally in our cardiovascular subspe- Results from Washington University that will be presented cialty. However, the harnessing of genetic engineering to reflect vigorous efforts by many colleagues. In addition, we produce thrombolytic drugs with promising properties now have had extensive help from numerous talented and gracious benefits patients with heart disease (4). Several practical collaborators from centers throughout the world, such as pharmacologic targets can be approached by genetic engi- Desire Cohen at the University of Leuven.
    [Show full text]
  • THROMBOSIS and THROMBOEMBOLISM 2020 Comprehensive Updates for Prevention, Diagnosis, Treatment Boston, MA
    Earn up to 15.75 AMA PRA Category 1 Credits™ 15.75 ABIM MOC points 15.75 AAFP Prescribed credits 15.75 CNE contact hours Education for PHYSICIANs, NPs, PAs Oct 8–9 THROMBOSIS AND THROMBOEMBOLISM 2020 Comprehensive Updates for Prevention, Diagnosis, Treatment Boston, MA This program is among the highest-rated Harvard Medical School CME Courses. PREVENTION Guidance and state-of-the-art approaches to: • Acute coronary syndromes DETECTION • Dual antiplatelet therapy, new oral anticoagulants, DIAGNOSIS and interventional devices • Pulmonary embolism and DVT TREATMENT • LDL and triglyceride reduction DEVICES • Stroke prevention in atrial fibrillation PROCEDURES • Genetics, thrombosis, and personalized medicine Samuel Z. Goldhaber, MD Register at Thrombosis.HMSCME.com Paul M Ridker, MD, MPH This special program is offered once every two years. Early registration is advised. Full agenda inside. Dear Colleague: Our understanding of thrombosis and thromboembolism has evolved rapidly. Advances in prevention, diagnosis, management, epidemiology, and pathophysiology will improve our clinical practice and yield more favorable patient outcomes. Since 1997, this CME course, Thrombosis and Thromboembolism, has been providing practical and timely education about these innovations in the field. Our upcoming 2020 curriculum promises to be the best in this program’s 23-year history, with master clinicians updating and guiding us so we can integrate these changes into our daily practice. This biennial course provides an opportunity to quickly, efficiently,
    [Show full text]
  • Eugene Braunwald M.D
    Postgraduate Medical Journal (December 1976) 52, 733-738. Postgrad Med J: first published as 10.1136/pgmj.52.614.733 on 1 December 1976. Downloaded from Coronary artery bypass surgery-an assessment EUGENE BRAUNWALD M.D. Department of Medicine, Harvard Medical School, and Peter Bent Brigham Hospital, Boston, Massachusetts 02115 Introduction form of therapy that can, under appropriate circum- The surgical treatment of coronary artery disease stances, favourably alter the clinical expression of has a long, chequered and, until recently, undistin- arteriosclerotic coronary artery disease. Accompany- guished history. It has gone through a number of ing this widespread optimism, however, is a growing stages; surgical sympathectomy was suggested to- uneasiness that by simple common consent, rather wards the end of the last century and was reported than by rational analysis of data, we may be adopting as a successful treatment for angina pectoris in 1916; for general use a form of treatment that has yet to abrasion of the epicardium and of the pericardium prove itself. Some fear that even though the long- was introduced in the 1930s; the application of a term effectiveness of direct revascularization has not variety of pedicles or organs (omentum or spleen) yet been demonstrated, we may be propelled into a to the surface of the heart was introduced in the position in which it will be considered poor medical early 1940s; occlusion of the coronary sinus was practice to withhold this form oftherapy from almost carried out later in the same decade; anastomosis any patient with coronary artery disease and in Protected by copyright.
    [Show full text]
  • EUGENE BRAUNWALD, M.D. Is the Distinguished Hersey Professor Of
    EUGENE BRAUNWALD, M.D. is the Distinguished Hersey Professor of Medicine at Harvard Medical School, and the founding Chairman of the TIMI Study Group at the Brigham and Women’s Hospital. Dr. Braunwald received his medical training at New York University and completed his Medical Residency at the Johns Hopkins Hospital. He served as the first Chief of the Cardiology Branch and as Clinical Director of the National Heart, Lung and Blood Institute, founding Chairman of the Department of Medicine at the University of California, San Diego. From 1972 to 1996 he was Chairman of the Department of Medicine at the Brigham and Women's Hospital. He was a founding trustee and Chief Academic Officer of Partners HealthCare System. Dr. Braunwald’s first major paper was published in Circulation Research in July 1954, and he has been a major force in cardiology in the past half century. His early work focused on the control of ventricular function and he was the first to measure both left ventricular ejection fraction and left ventricular dp/dt in patients. His group showed the first neurohumoral defect in human heart failure, defined the pathophysiology of hypertrophic cardiomyopathy and demonstrated salvage of ischemic myocardium following coronary occlusion. They defined myocardial stunning and ventricular modeling following myocardial infarction. For the past 30 years, as Chairman of the TIMI Study Group, he and his colleagues demonstrated improved patient survival with a patent coronary artery which led to the widely accepted “open artery hypotheses.” They were the first to show the benefit of preventing adverse remodeling of the infarcted ventricle with ACE inhibition.
    [Show full text]
  • Curriculum Outline and Syllabus of the Doctor Of
    CURRICULUM FOR DM COURSE IN CARDIOLOGY MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES NASHIK CURRICULUM FOR DM COURSE IN CARDIOLOGY Components of curriculum Section I. Statement of goals & specification of objectives. Section II. Selection & description of course contents (Syllabus) Section III. Recommended teaching learning methods and activities Section IV. Organization and scheduling of course Section V. Evaluation scheme Section VI. Recommended books and other learning resource materials. SECTION I. STATEMENT OF GOALS & SPECIFICATION OF OBJECTIVES A. Goal The goal of DM Cardiology programme is to provide specialized training in Cardiology to produce competent superspecialists. These specialists will be capable of providing care of the highest order to the cardiac patients in the community as well as clinical tertiary care centres. They would subsequently serve as teachers, trainers, researchers and leaders in the field of Cardiology. They shall recognize the health needs of the community, & carry out professional obligations ethically & in keeping with the objectives of the National Health Policy. B. Learning Objectives In general , the course is designed to train post graduates ( MD) in Internal Medicine & Pediatrics , in major areas of cardiology like clinical cardiology, coronary care ,pediatric cardiology, electrophysiology , invasive diagnostic and therapeutic cardiac procedures and various noninvasive diagnostic techniques and research activities. The aim of the course is to impart thorough and comprehensive training to the candidate in the various aspects of this so that at the end of the course he/she shall be able to perform the following Cognitive Domain: 1) To diagnose cardiovascular diseases based on clinical methods. 2) To interpret relevant laboratory, radiological and cardio logical investigations for the purpose of diagnosis 3) To arrive at a treatment plan/s based on 1 & 2 and discuss the pros and cons with the patient and his family.
    [Show full text]
  • MAP Directory of Award Recipients and Board Members
    MAP Directory of Award Recipients and Board Members Abul K. Abbas, MBBS Visiting Professor - Pfizer Visiting Professorships in Allergic Diseases and Asthma (2001) Awarded Institution: Creighton University School of Medicine Visiting Professor Host: Thomas B. Casale , MD (Creighton University School of Medicine) Francois M. Abboud, MD Board Member - ACCF/Pfizer Career Development Awards in University of Iowa Clinical or Preventive Cardiovascular Medicine (2000 - 2004) Iowa City, IA Board Member - ACCF/Pfizer Postdoctoral Fellowship Awards in Cardiovascular Medicine (2000 - 2004) Visiting Professor Host - Pfizer Visiting Professorships in Allergic Diseases and Asthma (1997) Awarded Institution: University of Iowa Visiting Professor: Jack A. Elias , MD (Yale University) Visiting Professor - ACCF/Pfizer Visiting Professorships in Preventive Cardiovascular Medicine (1986) Awarded Institution: Medical College of Virginia Visiting Professor Host: Hermes A. Kontos , MD, PhD (Medical College of Virginia) Sponsor - Pfizer Fellowships - Postdoctoral - Various Areas (1985) Awarded Institution: Awardee: Brian D. Miller , MD Evan Dale Abel, MD, PhD The University of Utah School of Medicine Visiting Professor Host - Pfizer Visiting Professorships in Salt Lake City, UT Diabetes (2010) Awarded Institution: The University of Utah School of Medicine Visiting Professor: Clay F Semenkovich , MD (Washington University in St. Louis School of Medicine) Visiting Professor Host - Pfizer Visiting Professorships in Obesity (2009) Awarded Institution: The University
    [Show full text]
  • Thrombolysis in Myocardial Infarction (TIMI) Study Group JACC Focus Seminar 2/8
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 77, NO. 22, 2021 ª 2021 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER JACC FOCUS SEMINAR: THE BEST OF POPULATION RESEARCH STUDIES JACC FOCUS SEMINAR Thrombolysis In Myocardial Infarction (TIMI) Study Group JACC Focus Seminar 2/8 Marc S. Sabatine, MD, MPH, Eugene Braunwald, MD ABSTRACT In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial Infarction) Study Group was born. Following completion of 3 clinical trials of thrombolytic therapy supported by the NHLBI, TIMI became an academic research organization headquartered at Brigham and Women’s Hospital and subsequently branched out to study a wide range of patients, including those with stable coronary, cerebrovascular, and peripheral arterial disease; dyslipidemia; heart failure; atrial fibrillation; diabetes; and obesity. TIMI also began to study a wide range of interventions including thrombolytic, antithrombotic, lipid-modifying, anti-inflammatory, heart failure, glucose-lowering, and weight loss agents. TIMI, now in its 37th year, has completed >70 trials. This review describes the origins of the TIMI Study Group, summarizes several of its completed trials and the major lessons learned from them, and discusses ongoing trials and future directions. (J Am Coll Cardiol 2021;77:2822–45) © 2021 by the American College of Cardiology Foundation. ORIGINS OF TIMI AND THE FIRST TRIALS Physiology of the National Heart Institute (now the National Heart, Lung, and Blood Institute [NHLBI]) THE ORIGINS. In the 1950s, it was generally agreed headed by Dr.
    [Show full text]
  • Jci.Org/Kiosk/Cgm
    Conversations with giants in medicine A conversation with Eugene Braunwald Eugene Braunwald (Figure 1) is often carried out in probably 4,000 hospitals in give them relief from severe angina. We were called the father of modern cardiology, as the US. But, at that time there were only 12 in discussion with developing a large phase he was the first to define the pathophysiol- cardiac cath labs in the country. It was an 3 trial to get this device approved for mar- ogy of hypertrophic cardiomyopathy and eye-opening experience, to be in a serious keting, but coronary artery bypass graft sur- to demonstrate the salvage of ischemic research laboratory, and I became interested gery came on the scene and was superior to myocardium following coronary occlusion. in the pathophysiology of heart failure. carotid sinus nerve stimulation in relieving The full interview, with many more stories Later, I had a postdoctoral fellowship angina. But, all was not lost because it led about performing in the opera and his sem- with [Nobel Laureate] André Cournand, to my second, and more important, “aha” inal research discoveries, can be seen on the who also worked in Bellevue Hospital, moment in the spring of 1968. We told our JCI website, http://www.jci.org/kiosk/cgm. but in the Columbia University division. I patients that if they had unusually severe JCI: Can you tell us about your path to spent a year there and that firmed my inter- pain, not the usual angina, they shouldn’t medical school? est in research, and also led to my being turn their carotid sinus stimulators on Braunwald: I was born in Vienna, Austria, accepted by what was then the National because, if they were having an infarction, and had an idyllic childhood there with Heart Institute.
    [Show full text]
  • Acute Myocardial Infarction: a Century of Progress
    06_BRAUNWALD((OK)) 87-98.QXD_Layout 1 23/09/11 12:58 Pagina 89 Atherosclerosis: The 21st Century Epidemic Pontifical Academy of Sciences, Scripta Varia 116, Vatican City 2011 www.pas.va/content/dam/accademia/pdf/sv116/sv116-braunwald.pdf Acute Myocardial Infarction: A Century of Progress Eugene Braunwald The year 2010 marks the centenary of the first description of acute my- ocardial infarction (AMI). In 1910, Obraztsov and Strazhesko from Kiev in the Ukraine presented their landmark observation in five patients. Remarkably, in the very first paper on the subject, they described correctly the key clinical find- ings of this important condition. To quote them (translated from Ukranian): All patients noted an acute, sudden onset of the disease. Direct events often precipitated the disease; the infarct began in one case on climbing a high staircase, in another during an unpleasant conversation and in a third during emotional distress associated with a heated card game. They stated that the symptoms were of three types: 1. Substernal pain with radiation to the neck, head and left hand 2. Shortness of breath, reaching such a severe degree that it did not per- mit the patients to lie or sleep 3. Heaviness and severe pressure in the epigastrium Just three years later, Anitschkow and Chalatow (1913) produced athero- sclerotic lesions in the arteries of healthy rabbits who were fed a diet con- taining large quantities of fat, thereby raising the cholesterol concentration in the circulating blood to approximately 1000 mg/dl. From these two landmark observations – one clinical and the other ex- perimental – the mechanism of obstruction of coronary arteries secondary to atherosclerotic changes, and the serious clinical consequences of such obstruction, were firmly established.
    [Show full text]